Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $75.00 Price Target at TD Cowen

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price lowered by research analysts at TD Cowen from $86.00 to $75.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective would suggest a potential upside of 139.55% from the stock’s current price.

Several other brokerages also recently weighed in on RARE. Morgan Stanley cut their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, July 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, September 5th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Finally, Truist Financial reduced their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $82.31.

Ultragenyx Pharmaceutical Trading Down 3.5%

RARE traded down $1.15 during trading hours on Wednesday, hitting $31.31. 1,772,579 shares of the company’s stock were exchanged, compared to its average volume of 1,351,696. Ultragenyx Pharmaceutical has a 12-month low of $25.81 and a 12-month high of $53.47. The firm has a 50 day moving average of $31.40 and a 200 day moving average of $32.91. The firm has a market cap of $3.02 billion, a P/E ratio of -5.66 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business had revenue of $159.93 million for the quarter, compared to analysts’ expectations of $167.42 million. During the same period in the previous year, the company earned ($1.40) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 14.6% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, research analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Howard Horn sold 7,942 shares of the stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the transaction, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at $3,095,132.77. This trade represents a 7.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the transaction, the executive vice president directly owned 73,271 shares in the company, valued at $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 10,456 shares of company stock worth $328,486 over the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of RARE. GAMMA Investing LLC boosted its stake in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 323 shares during the period. Parallel Advisors LLC boosted its stake in Ultragenyx Pharmaceutical by 1,061.9% during the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 669 shares during the period. Covestor Ltd boosted its stake in Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth $55,000. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth $57,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.